Effect of supplementation in treatment of pregnancy complications

Effects of vitamin D supplementation on metabolic profiles in pregnant women who are at risk of pre-eclampsia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201410035623N27

Enrollment

Registered

2014-10-04

Start date

2014-06-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy. Sequelae of complication of pregnancy, childbirth and the puerperium

Interventions

Intervention 1: Intervention group: Vitamin D pearl, 50000 IU, each two weeks for 12 weeks. Intervention 2: Control group: Placebo pearl, each two weeks for 12 weeks.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Pregnant women primigravida Aged 18-40 years old At risk for pre-eclampsia

Exclusion criteria

Exclusion criteria: Unable or unwilling to give written informed consent Abnormal fetal anomaly scan Treated with warfarin

Design outcomes

Primary

Measure	Time frame
Pre-eclampsia rate. Timepoint: After delivery. Method of measurement: Medical record.;Low birth weight (LBW) (<2500 g). Timepoint: After delivery. Method of measurement: Scale.;Newborn's birth size. Timepoint: After delivery. Method of measurement: Scale and tape.;Preterm delivery (<37 weeks). Timepoint: After delivery. Method of measurement: Medical record.	—

Secondary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Eliza.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Blood pressures. Timepoint: Baseline and End-of-trial. Method of measurement: Manometer.	—

Measure

Time frame

Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Eliza.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Blood pressures. Timepoint: Baseline and End-of-trial. Method of measurement: Manometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 985 546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026